Raw materials valued at Rs 12.4 lakh used to illegally make veterinary medicines seized, 5 booked

Thane: A stock of raw materials valued at Rs 12.4 lakh, intended for the illegal production of veterinary medicinal products, has been discovered at a factory in Maharashtra’s Thane district, police said.

An FIR has been registered against five individuals, including the factory owner, in connection with the case.

Following a tip, the police and Food and Drug Administration (FDA) personnel raided the unit located at Roshan Baug-Faizan Compound in Bhiwandi town on Monday, the official from Bhoiwada police station told PTI.
They seized a stock of raw materials including chemicals and other items valued at Rs 12.4 lakh, he said.
Since the last five months, the accused were manufacturing the products illegally without possessing a permit or having any formal training for the production of medicines, the official said.
A case was registered under provisions of the Drugs and Cosmetics Act against the factory owner and four others who helped in the supply of raw materials and the sale and distribution of the medicines, the police added.
Recently, the Narcotics Control Bureau (NCB) has also dismantled an interstate drug syndicate operating from Ulhasnagar in Thane district. During a two-day operation, NCB seized Codeine syrup bottles and marijuana with an collective estimated value of Rs 1.75 crore from six individuals.

Read also: 4,800 bottles of Codeine syrup bottles seized in Thane


Powered by WPeMatico

Intas Pharmaceuticals Gets CDSCO Panel Nod to Study Vedolizumab for Ulcerative Colitis

New Delhi: Intas Pharmaceuticals has got the go-ahead from the Subject Expert Committee ( SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct a Phase III clinical trial to compare the efficacy, safety, immunogenicity, and pharmacokinetics of the proposed biosimilar of Vedolizumab (INTP53) Intravenous Injection and Vedolizumab reference for induction and maintenance therapy in patients with moderate to severely active ulcerative colitis.

This came after Intas Pharmaceuticals presented the proposal for grant of permission to conduct a Phase III clinical trial as per the protocol titled “A Phase III, Randomized, Double-Blind, Multicenter, Active-Controlled, Two-Arm, Parallel Group Study to Compare the Efficacy, Safety, Immunogenicity and Pharmacokinetics of the Proposed Biosimilar of Vedolizumab (INTP53) Intravenous Injection and Vedolizumab Reference for Induction and Maintenance Therapy in Patients with Moderate to Severe Active Ulcerative Colitis” vide protocol number: 0046-24 Version No.1.0, Dated 23-02-2024.

Vedolizumab is an integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn’s disease in adults. Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative colitis or Crohn’s disease.

At the recent SEC meeting on gastroenterology and hepatology held on July 25, 2024, the expert panel reviewed the proposal for grant of permission to conduct a Phase III clinical trial protocol presented by the drug major Intas Pharmaceuticals.

After detailed deliberation, the committee recommended conducting the Phase III clinical trial as per the protocol presented by the firm.

Also Read: Pfizer Gets CDSCO Panel Nod for Active PMS Study of FDC Levonorgestrel Plus Ethinyloestradiol Tablets

Powered by WPeMatico

Kolkata Doctor Rape Case: IMA Chief meets JP Nadda, calls for central law on doctor safety

New Delhi: In response to the recent brutal rape and murder of PG respiratory medicine medico at R G Kar Medical College and Hospital, a delegation from the Indian Medical Association (IMA) met with the Union Health Minister JP Nadda today to address concerns related to doctor’s safety across the country.

During the meeting, a memorandum was submitted demanding the declaration of hospitals across the country as safe zones, a central law against violence and NMC to bring in security stipulations for recognition of medical colleges. 

In response to the doctors’ demands, the Honourable Health Minister assured that the Government would consider the first two demands while he accepted the NMC stipulations on security. 

“IMA pressed for better working conditions and accommodation for Resident doctors. The minister responded positively to this demand as well. IMA considers this meeting as the first step in the resolution of the issue. IMA awaits the final word from the Government on the first two demands,” stated a press release by the association. 

The IMA team, comprised of National President Dr R V Asokan, HSG Dr Anilkumar J Nayak, Past National President Dr Vinay Aggarwal, and HFS Dr Shitij Bali who met with Union Health Minister Shri J.P. Nadda at 2:30 PM, accompanied by Shri Apurva Chandra, Secretary (Health & Family Welfare, GoI), and Dr Atul Goel (Director General, DGHS, GoI). 

This comes after the Union health minister invited the IMA team comprising of National President Dr RV Asokan, HSG Dr Anil J Nayak Past National President Dr Vinay Aggarwal and HFS Dr Shitij Bali for a meeting today following the submission of a letter. 

Previously, the association wrote a letter to the Union Health Minister urging the government to fulfil their demands regarding the violence against doctors across the country and the need for the government to declare hospitals as ‘safe zones’.

Also read- AIIMS cites code of conduct, Doctors refuse to back down from strike

Their other demands mentioned in the letter include – All major Government hospitals should have police camps and adequate security personnel, Similar security arrangements should be made mandatory in large private hospitals and CCTV cameras in vulnerable points should be made compulsory.

In addition, the association also stated in the letter, “25 states have law on attack on doctors and hospitals. They are mostly ineffective on the ground and do not serve the purpose of deterrence. The absence of a special central enactment is one of the reasons. We kindly request you to reconsider introducing the Draft Legislation The Healthcare Service Personnel and Clinical Establishments (Prohibition of Violence and Damage to Property) Bill, 2019 incorporating the amendments in the Epidemic Diseases Act 1897, approved and passed by the Parliament in Epidemic Diseases (Amendment) Act, 2020.”

Before the meeting, Dr RV Asokan, President of the Indian Medical Association (IMA), told ANI, “Our demands are two-fold. Our demands to the Union government have been pending for the past two decades. We want the Union government to declare hospitals as ‘safe zones’. What we have in mind is a layered security structure for hospitals. This has to be defined by law and enforced by local authorities. 

We have state legislation on violence against doctors/healthcare workers in 25 states. On the ground, it is found to be not practical as a central law is not in place. It is time that they relook at a central law. There are more and more women doctors in India now, and it is the responsibility of the government to ensure their safety….,” he adds.

“We will be meeting him (Union Health Minister JP Nadda) today. Tomorrow, we will meet the West Bengal CM and press for early resolution of our demands,” says IMA President on the rape-murder of a lady doctor at R G Kar Medical College and Hospital in Kolkata. 

Also read- PG medico rape-murder at RG Kar Medical College: IMA issues 48-hour ultimatum, threatens nationwide protest

Powered by WPeMatico

Man held for threatening doctor with same fate as RG Kar PG Medico

The safety of women doctors across the country was once again challenged recently when a man in Bengal’s Purba Bardhaman district threatened a lady doctor of a similar fate as the rape and murder of the PG doctor at R G Kar Medical College, Kolkata.
PTI has reported that the man- Susanta Roy was a patient, who threatened the female doctor if his treatment was delayed. Roy was arrested after doctors and nurses of the state-run Bhatar State General Hospital staged a protest against the incident.
For more information, click on the link below:

Powered by WPeMatico

Routine lab tests are not a reliable way to diagnose long COVID, finds study

A National Institutes of Health (NIH)-supported study has found that routine lab tests may not be useful in making a long COVID diagnosis for people who have symptoms of the condition. The study, part of NIH’s Researching COVID to Enhance Recovery (NIH RECOVER) Initiative and published in the Annals of Internal Medicine, highlights how challenging it can be to identify and diagnose a novel illness such as long COVID.

Powered by WPeMatico

Brain biomarker in blood sample predicts stroke, researchers demonstrate

Researchers at Uppsala University Hospital and Uppsala University have demonstrated that a simple blood test that reflects brain health can predict which people are most at risk of suffering a stroke. The discovery could contribute to more individualized treatment of patients with atrial fibrillation. The study has been published in the journal Circulation.

Powered by WPeMatico

Engineered exosome-based drug delivery system shows promise for ovarian cancer therapy

Ovarian cancer is one of the most common malignancies in women worldwide. Unlike breast cancer, ovarian cancer lacks early diagnostic markers and does not show noticeable symptoms until cancer metastases, leading to a low survival rate for ovarian cancer patients. Traditional cancer treatments include surgery, radiation therapy, chemotherapy and interventional therapy. However, the distribution of chemotherapeutic drugs in vivo is non-specific and often toxic to healthy cells, leading to unsatisfactory efficacy.

Powered by WPeMatico

Q&A: Researcher discusses why ‘hope scrolling’ can be a good idea

It’s no secret that the news has been full of doom and gloom. Algorithms have made doomscrolling, the act of consuming large amounts of dire content, all the easier because the more you look at a type of content, the more it is fed to your channels.

Powered by WPeMatico

Q&A: Generative AI ‘drift’ and ‘nondeterminism’ inconsistences are important considerations in health care applications

Samuel (Sandy) Aronson, ALM, MA, executive director of IT and AI Solutions for Mass General Brigham Personalized Medicine and senior director of IT and AI Solutions for the Accelerator for Clinical Transformation, is the corresponding author of a paper published in NEJM AI that looked at whether generative AI could hold promise for improving scientific literature review of variants in clinical genetic testing. Their findings could have a wide impact beyond this use case.

Powered by WPeMatico

LENS trial a first of its kind large scale trial shows striking 27% reduction in diabetic retinopathy progression

Presented at the ADA Diabetes Congress 2024, the LENS TRIAL was specifically designed to investigate the effect of Fenofibrate on eye outcomes in people with early diabetic retinopathy.

Over the period of four years, this trial, involving 1,151 participants, has yielded promising results in the favor of Fenofibrate:

● 27% lower risk of progression of diabetic retinopathy

● 50% reduction in the development of macular edema

● 42% reduction in the need for treatment intervention

The benefits of fenofibrate were similar in people with both T1DM and T2DM and in people with both normal and impaired kidney function

Dr. David Preiss, Associate Professor at Oxford University & Principal investigator of LENS trial, shared his expert opinion, highlighting Fenofibrate as a valuable addition to treat people with diabetic retinopathy.

Reference:

1) ADA 2024,
Scientific Sessions: The Effect of Fenofibrate on Progression of Diabetic
Retinopathy—Results from the LENS Trial Presented on Friday, June 21, 2024, at
3:45 PM EDT.

Powered by WPeMatico